5PSQ-037 Analysis of human immunodeficiency virus postexposure prophylaxis in a third-level hospital

BackgroundThe World Health Organisation recognises the need to improve uptake and completion rates for postexposure prophylaxis (PEP).PurposeTo analyse PEP dispensed by the pharmacy service to patients after an occupational (OE) or nonoccupational (NOE) exposure to the human immunodeficiency virus (...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A218-A219
Main Authors: Estaun, C, Moya-Carmona, I, Sánchez-Yañez, E, Fernández-Ovies, JM
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Clinical medicine
HIV
Human immunodeficiency virus
Infections
Patients
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe World Health Organisation recognises the need to improve uptake and completion rates for postexposure prophylaxis (PEP).PurposeTo analyse PEP dispensed by the pharmacy service to patients after an occupational (OE) or nonoccupational (NOE) exposure to the human immunodeficiency virus (HIV).To compare usual clinical practice in our centre for PEP to European acquired immune deficiency syndrome (AIDS) Clinical Society guidelines.1Material and methodsA descriptive, observational and retrospective study performed in a third-level hospital regarding PEP dispensed from January 2015 to March 2018. The following data were retrieved from an electronic prescription program management tool (outpatients’ clinical module) and electronic clinical records: sex, age, year, time from exposure, nature of exposure (sexual contact (SC) vs blood contact (BC)), OE vs NOE, service of the prescribing doctor, antiretroviral drugs (AD) prescribed, following monitoring in outpatient visit, positive infection detected after PEP, further episodes of PEP and positive infection nowadays.We reviewed the current version of the European AIDS Clinical Society guidelines.1ResultsCurrent guidelines recommend 4 week treatment with AD after OE or NOE as early as possible (no later than 48/72 hours). PEP regimen: emtricitabine/tenofovir disoproxilfumarato (FTC/TDF)+raltegravir (RAL) or darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r). Re-evaluation of PEP indication by HIV experts is recommended within 48–72 hours.Clinical records of 57 patients were analysed: distribution per year 2015 24.5% (n=14), 2016 33.3% (n=19), 2017 33.3% (n=19), 2018 8.7% (n=5). Median age 29.9 years, 77.2% (n=44) males. Time from exposure
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.470